• Skip to main content
  • Skip to footer

Akari Therapeutics

A Revolution in Treating Autoinflammatory & Orphan Diseases

Menu
  • HOME
  • ABOUT
    • Close
    • MANAGEMENT
    • BOARD OF DIRECTORS
  • LEAD INDICATIONS
    • Close
    • OVERVIEW
    • BP PIVOTAL
    • TMA-HSCT PIVOTAL
    • OPHTHALMIC CONDITIONS
    • PULMONARY CONDITIONS
    • PRECLINICAL PROGRAMS
      • Close
      • NOMACOPAN LA
      • VOTUCALIS
      • OTHER INDICATIONS
  • THE SCIENCE
    • Close
    • OVERVIEW
    • MODE OF ACTION
    • TARGET PATHWAYS
      • Close
      • C5 (COMPLEMENT SYSTEM)
      • LTB4 (LEUKOTRINE SYSTEM)
    • MOLECULES
      • Close
      • NOMACOPAN
      • OTHER NOMACOPAN-BASED MOLECULES
      • VOTUCALIS
  • INVESTOR RELATIONS
    • Close
    • OVERVIEW
    • GENERAL MEETING OF SHAREHOLDERS
    • FINANCIAL INFORMATION
      • Close
      • SEC FILINGS
      • ANNUAL REPORTS
    • NEWS & EVENTS
      • Close
      • PRESS RELEASES
      • EVENTS
      • PRESENTATIONS
    • STOCK INFORMATION
      • Close
      • STOCK QUOTE & CHART
      • HISTORIC PRICE LOOKUP
      • INVESTMENT CALCULATOR
    • CORPORATE GOVERNANCE
      • Close
      • GOVERNANCE OVERVIEW
      • BOARD OF DIRECTORS
      • MANAGEMENT
      • COMMITTEE COMPOSITION
    • INVESTOR RESOURCES
      • Close
      • INVESTOR FAQS
      • EMAIL ALERTS
  • PRESS
    • Close
    • PRESS RELEASES
    • PUBLICATIONS
    • BLOG
  • CONTACT US

Press Release

Akari TX / May 19, 2022

Akari Therapeutics Presents Results from the CASCADE and CORONET Studies in COVID-19 at the American Thoracic Society (ATS) 2022 Annual Meeting

NEW YORK and LONDON, May 19, 2022 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company focused on developing advanced …

[Read more...] about Akari Therapeutics Presents Results from the CASCADE and CORONET Studies in COVID-19 at the American Thoracic Society (ATS) 2022 Annual Meeting

Akari TX / May 16, 2022

Akari Therapeutics Reports Full Year 2021 Financial Results and Highlights Clinical Progress

Clinical trial sites open and enrolling patients in FDA and EMA registration-directed Phase III Part A study of nomacopan in pediatric hematopoietic stem cell …

[Read more...] about Akari Therapeutics Reports Full Year 2021 Financial Results and Highlights Clinical Progress

Akari TX / May 11, 2022

Akari Therapeutics to Present Results from Compassionate Use of Nomacopan for COVID-19 (CORONET) and Identification of Clinical Deterioration Risk in COVID-19 (CASCADE) atthe American Thoracic Society (ATS) 2022 Annual Meeting 

NEW YORK and LONDON, May 11, 2022 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company …

[Read more...] about Akari Therapeutics to Present Results from Compassionate Use of Nomacopan for COVID-19 (CORONET) and Identification of Clinical Deterioration Risk in COVID-19 (CASCADE) atthe American Thoracic Society (ATS) 2022 Annual Meeting 

Akari TX / May 10, 2022

Akari Therapeutics Announces Publication of Phase II Data of Investigational Nomacopan for the Treatment of Bullous Pemphigoid (BP) in JAMA Dermatology 

• Patients received subcutaneous nomacopan (30 mg once daily) with lesional mometasone from Day 1 to 21 of treatment and nomacopan only …

[Read more...] about Akari Therapeutics Announces Publication of Phase II Data of Investigational Nomacopan for the Treatment of Bullous Pemphigoid (BP) in JAMA Dermatology 

Akari TX / May 9, 2022

Akari Presents Results from Two Preclinical Development Programs of Long-Acting PAS-Nomacopan in Geographic Atropy (GA) Dry Age-Related Macular Degeneration and Nomacopan in Experimental Immune-Mediated Conjunctival Disease (EIC)

• Preclinical data show investigational intravitreal long-acting PASylated-nomacopan (PAS-nomacopan) effective in inhibiting choroidal neovascularization (CNV), …

[Read more...] about Akari Presents Results from Two Preclinical Development Programs of Long-Acting PAS-Nomacopan in Geographic Atropy (GA) Dry Age-Related Macular Degeneration and Nomacopan in Experimental Immune-Mediated Conjunctival Disease (EIC)

Next Page »

Footer

Akari TX

LONDON

75/76 Wimpole Street London W1G 9RT UK

T: +44 (0)20.8004.0261
E: info@Akaritx.com

NEW YORK

1460 Broadway
New York, NY 10036

T: 929.274.7510
F: 929.274.7553
E: info@Akaritx.com

For investor relations inquiries: IR@akaritx.com
For business development inquiries: BD@akaritx.com

REGISTERED ADDRESS

Akari Therapeutics, Plc is registered in England and Wales under number 5252842 and has its registered office at Highdown House, Yeoman Way, Worthing, West Sussex, BN99 3HH.

EXPANDED ACCESS POLICY

In severe or life-threatening conditions where there are no available treatment options, regulators may grant permission to provide a treating physician access to an unapproved drug; this is known as expanded access.  At this time, the safety and effectiveness of nomacopan to treat diseases such as Atopic Keratoconjunctivitis (AKC), Bullous Pemphigoid (BP); Thrombotic Microangiopathy (TMA), and Paroxysmal Nocturnal Hemoglobinuria (PNH) has not been established. Until more data are available, Akari Therapeutics is not considering requests for expanded access outside of clinical trials. This policy may change as safety and efficacy are better demonstrated. For questions regarding our current expanded access policy, please contact Akari Therapeutics at +44 (0)20-8004-0261.

Copyright © 2022 · Akari Therapeutics · Site Designed by Polus Digital, Inc.